Deferasirox Supplier in Kyrgyzstan
DEFRATAJ — WHO-GMP Deferasirox dispersible tablets, supplied direct from the manufacturer to DDFP-registered importers.
Supply & Market
Taj Pharma supplies Deferasirox dispersible tablets to Kyrgyzstan as a WHO-GMP manufacturer with Russian, English and Cyrillic-labelled packaging options. DEFRATAJ reaches Taj Pharma India Ltd. through Saint-Petersburg and Vladivostok ports as well as overland routes via Kazakhstan, supporting hospital-tender and distributor channels.
The Kyrgyzstan market for iron-chelation therapy is driven by transfusion-dependent thalassemia, sickle-cell disease and myelodysplastic syndromes, where Deferasirox dispersible tablets are widely prescribed under the WHO Essential Medicines List.
Our regulatory and commercial team in Mumbai partners directly with importers, hospital procurement officers and Ministry-of-Health tender desks across Kyrgyzstan — from Bishkek to regional referral centres — for streamlined supply continuity.
Supply Capability for Kyrgyzstan
DEFRATAJ is supplied to Kyrgyzstan across all five strengths — 100 mg, 125 mg, 250 mg, 400 mg and 500 mg dispersible tablets — in HDPE bottles (30s/60s/100s) and Alu-Alu blister packs. Minimum-order quantities start at 50,000 tablets per strength with a typical lead time of 4–6 weeks from PO confirmation.
- Strengths shipped: 100 mg, 125 mg, 250 mg, 400 mg, 500 mg dispersible tablets
- Pack sizes: bottles (30/60/100 tabs), Alu-Alu blisters (10x10), hospital institutional packs
- MOQ: 50,000 tablets per strength per shipment (mixed pallets supported)
- Lead time: 4–6 weeks ex-Mumbai (JNPT / Nhava Sheva)
- Shelf life: 24 months at 25°C / 60% RH (Zone IVb stability data on file)
- Documents per shipment: CoA, CoO, packing list, invoice, BL/AWB, free-sale certificate
- Private label / co-branding: available with own artwork and brand registration
Cold-chain is not required for dispersible tablets, but climatised containers can be arranged on request for hot-route lanes into Kyrgyzstan.
Regulatory Pathway in Kyrgyzstan
Deferasirox dispersible tablets are registered in Kyrgyzstan with the Department of Drug Provision and Medical Equipment (DDFP). Taj Pharma submits the full CTD dossier (Modules 1–5) along with our WHO-GMP certificate, CoPP, manufacturing licence, plant master file and validated stability data to DDFP. Our regulatory desk handles queries, sample submissions and post-approval variations on behalf of local marketing-authorisation holders.
Local agent appointment, secondary packaging in Kyrgyz, Russian, and pharmacovigilance reporting are all coordinated from our Mumbai head office. Documentation can be couriered or e-submitted to DDFP in Bishkek.
- CTD dossier (Modules 1–5) ready
- WHO-GMP · ISO 9001 · PIC/S-aligned plant
- CoPP & manufacturing licence on request
- Stability data (long-term & accelerated, Zone IVb)
- Country code
KG· trade currency Kyrgyzstani Som